Back to Research Platform
Immune
✓ Janoshik Verified

Thymosin Alpha-1

Also known as: TA1

Molecular Weight

3108 Da

Half-Life

2 hours

Administration

Subcutaneous injection

Longevity Score

8/10

Mechanism of Action

A 28-amino acid immunomodulating polypeptide that stimulates both innate and adaptive immune responses. Activates Toll-like receptors and downstream signaling pathways. Restores immune homeostasis and enhances T-cell function, dendritic cell maturation, and cytokine production.

Research-Backed Benefits

  • Enhanced immune function via TLR activation
  • Improved vaccine response
  • Anti-viral properties (HIV, hepatitis)
  • Reduced inflammation
  • Synergistic with chemotherapy for anti-tumor response

Dosing Protocols

beginner

0.8mg 2x/week

intermediate

1.0mg 3x/week

advanced

1.5mg 3x/week

athlete

1.5mg 3x/week

Frequency: 3x weekly · Duration: 8–12 weeks per cycle, with 4-week breaks between cycles

Expected Results Timeline

Week 1-2

Improved energy, reduced minor illness duration

Week 3-4

Notable immune resilience, better recovery

Week 5-8

Significant immune optimization, enhanced CD8+ T-cell response

Long Term

Sustained immune function improvement

Safety & Risks

  • Injection site reactions
  • Rare allergic reactions

Contraindications:

  • Organ transplant recipients
  • Autoimmune conditions requiring immunosuppression

Notable Research

Thymosin alpha-1 in hepatitis B treatment (2008)

Demonstrated antiviral efficacy in chronic hepatitis B patients

DOI: 10.1016/j.jhep.2008.03.023

Explore more peptides in this category

View All Immune Peptides →

Related Guides

Research Disclaimer: This information is compiled from published research and is provided for educational purposes only. Peptides discussed here are classified as research chemicals in most jurisdictions and are not FDA-approved for human use unless otherwise noted. Consult a qualified healthcare provider before starting any protocol.